Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and DDI Study of HLX208 in Healthy Subjects
NCT05902728Phase 1Completed
- Sponsor
- Henlius
- Start
- Jul 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HLX208 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Henlius. Primary endpoints: Maximum Plasma Concentration up to 48 hours, Area Under the Curve from time 0 to last measurable concentration up to 48 hours and 1 more. Started Jul 2023; status: completed.
02
Drugs
HLX208
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05902728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902728.